• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

结肠癌中 N6-甲基腺苷 RNA 甲基化调节因子 IGF2BP3 的异常表达预示着预后不良。

Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.

机构信息

Department of Colorectal Surgery, Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, China.

Dermatology, Kunming Children's Hospital, Kunming, China.

出版信息

Dis Markers. 2022 May 30;2022:5883101. doi: 10.1155/2022/5883101. eCollection 2022.

DOI:10.1155/2022/5883101
PMID:35677634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9170420/
Abstract

The value of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), an N6-methyladenosine (m6A) RNA methylation regulatory factor, in the prognosis of colon cancer was still unclear. High levels of IGF2BP3 were expressed in colon adenocarcinoma (COAD) samples and in human colon cancer tissues, which was associated with poorer overall survival (OS). We validated IGF2BP3 as an independent prognostic risk biomarker in COAD patients. Moreover, functional enrichment analysis suggested that differentially expressed genes (DEGs) of groups with high versus low IGF2BP3 expression were related to immune- and cancer-related pathways. Furthermore, the tumor microenvironments of high- versus low-IGF2BP3 expression groups showed significant differences and IGF2BP3 predicted the efficiency of immunotherapy. Finally, protein-protein interaction network analysis suggested that there was a direct or indirect interaction among IGF2BP3, WNT7B, VANGL2, NKD1, AXIN2, RNF43, and CDKN2A. In brief, IGF2BP3 was confirmed as an independent prognostic signature in COAD patients and might be a therapeutic target in this study. Moreover, IGF2BP3 could be used in personalized immunotherapy for COAD.

摘要

胰岛素样生长因子 2 mRNA 结合蛋白 3（IGF2BP3）作为 N6-甲基腺苷（m6A）RNA 甲基化调控因子的价值在结肠癌的预后中尚不清楚。IGF2BP3 在结肠腺癌（COAD）样本和人结肠癌组织中高表达，与总体生存（OS）较差相关。我们验证了 IGF2BP3 是 COAD 患者独立的预后风险生物标志物。此外，功能富集分析表明，IGF2BP3 高表达与低表达组的差异表达基因（DEGs）与免疫和癌症相关途径有关。此外，高 IGF2BP3 表达组与低 IGF2BP3 表达组的肿瘤微环境存在显著差异，IGF2BP3 预测了免疫治疗的效率。最后，蛋白质-蛋白质相互作用网络分析表明，IGF2BP3 与 WNT7B、VANGL2、NKD1、AXIN2、RNF43 和 CDKN2A 之间存在直接或间接的相互作用。总之，IGF2BP3 被确认为 COAD 患者独立的预后标志物，并且可能是本研究中的治疗靶点。此外，IGF2BP3 可用于 COAD 的个性化免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/ccf5dd2df7d6/DM2022-5883101.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/8fbf93648d8b/DM2022-5883101.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/3b4459ab0e9f/DM2022-5883101.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/96934d37db6a/DM2022-5883101.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/bdef2b2cedcc/DM2022-5883101.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/e27404c595ab/DM2022-5883101.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/d52555ed6ef6/DM2022-5883101.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/5f9c77c71525/DM2022-5883101.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/af5c10552a06/DM2022-5883101.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/ccf5dd2df7d6/DM2022-5883101.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/8fbf93648d8b/DM2022-5883101.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/3b4459ab0e9f/DM2022-5883101.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/96934d37db6a/DM2022-5883101.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/bdef2b2cedcc/DM2022-5883101.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/e27404c595ab/DM2022-5883101.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/d52555ed6ef6/DM2022-5883101.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/5f9c77c71525/DM2022-5883101.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/af5c10552a06/DM2022-5883101.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/9170420/ccf5dd2df7d6/DM2022-5883101.009.jpg

相似文献

1
Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.结肠癌中 N6-甲基腺苷 RNA 甲基化调节因子 IGF2BP3 的异常表达预示着预后不良。
Dis Markers. 2022 May 30;2022:5883101. doi: 10.1155/2022/5883101. eCollection 2022.
2
RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.RNA N6-甲基腺嘌呤阅读器 IGF2BP3 调节结肠癌中的细胞周期和血管生成。
J Exp Clin Cancer Res. 2020 Sep 29;39(1):203. doi: 10.1186/s13046-020-01714-8.
3
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.食管鳞癌中 PD-L1 表达、免疫浸润与 m6A RNA 甲基化调控因子的综合分析
Front Immunol. 2021 May 12;12:669750. doi: 10.3389/fimmu.2021.669750. eCollection 2021.
4
Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma.m6A 调控因子的综合分析及其与结直肠腺癌肿瘤微环境、免疫治疗策略的关系。
BMC Genom Data. 2023 Aug 11;24(1):44. doi: 10.1186/s12863-023-01149-y.
5
Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas.鉴定IGF2BP3作为胶质瘤的不良预后生物标志物
Front Genet. 2021 Oct 13;12:743738. doi: 10.3389/fgene.2021.743738. eCollection 2021.
6
Prognostic Impact of Expression in Patients with Surgically Resected Lung Adenocarcinoma.表达水平对手术切除的肺腺癌患者预后的影响。
DNA Cell Biol. 2021 Feb;40(2):316-331. doi: 10.1089/dna.2020.6136. Epub 2021 Jan 25.
7
Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.m6A 相关 lncRNA 特征分析预测结肠癌患者预后和免疫应答。
J BUON. 2021 Sep-Oct;26(5):1931-1941.
8
Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.多组学分析 N6-甲基腺苷读码器 IGF2BP3 作为泛癌的有前途的生物标志物。
Front Immunol. 2023 Jan 25;14:1071675. doi: 10.3389/fimmu.2023.1071675. eCollection 2023.
9
Comprehensive analysis of mA regulator-based methylation modification patterns characterized by distinct immune profiles in colon adenocarcinomas.基于 mA 调节剂的甲基化修饰模式的综合分析，其特征在于结肠腺癌中不同的免疫特征。
Gene. 2022 May 5;821:146250. doi: 10.1016/j.gene.2022.146250. Epub 2022 Feb 10.
10
Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.基于 m6A RNA 甲基化修饰和免疫微环境的肺腺癌分子亚型特征。
BMC Cancer. 2021 Aug 20;21(1):938. doi: 10.1186/s12885-021-08655-1.

引用本文的文献

1
RNA Binding Protein IGF2BP3 Rehabilitates Glycolysis of Vascular Endothelial Cells to Protect the ox-LDL-induced Cellular Injury via Stabilizing LDHA mRNA.RNA结合蛋白IGF2BP3通过稳定LDHA mRNA恢复血管内皮细胞的糖酵解，以保护氧化低密度脂蛋白诱导的细胞损伤。
Cell Biochem Biophys. 2025 Mar 30. doi: 10.1007/s12013-025-01735-0.
2
The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder.m6A 甲基化在肿瘤免疫和免疫相关疾病中的作用。
Biomolecules. 2024 Aug 22;14(8):1042. doi: 10.3390/biom14081042.
3
Comprehensive analysis of IGF2BP3 with expression features, prognosis, immune modulation and stemness in hepatocellular carcinoma and pan-cancer.

本文引用的文献

1
Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1.IGF2BP3与RNA m6A结合通过上调ABCB1触发HCT8细胞的化疗耐药性。
Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
2
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.微卫星不稳定高或错配修复缺陷转移性结直肠癌患者一线帕博利珠单抗与化疗治疗的健康相关生活质量（KEYNOTE-177）：一项开放标签、随机、III 期试验。
Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1.
3
肝细胞癌和泛癌中IGF2BP3的表达特征、预后、免疫调节及干性的综合分析
J Cancer. 2024 Mar 25;15(9):2845-2865. doi: 10.7150/jca.92768. eCollection 2024.
4
m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis.N6-甲基腺嘌呤（m6A）修饰对结直肠癌命运的影响：细胞增殖和肿瘤发生的功能及机制
Front Oncol. 2023 Apr 21;13:1162300. doi: 10.3389/fonc.2023.1162300. eCollection 2023.
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
结肠癌临床实践指南（2021 年第 2 版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-359. doi: 10.6004/jnccn.2021.0012.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer.IGF2BP3 通过调节人膀胱癌中的 JAK/STAT 信号通路促进细胞增殖和肿瘤发生。
J Cell Mol Med. 2020 Dec;24(23):13949-13960. doi: 10.1111/jcmm.16003. Epub 2020 Oct 22.
6
RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.RNA N6-甲基腺嘌呤阅读器 IGF2BP3 调节结肠癌中的细胞周期和血管生成。
J Exp Clin Cancer Res. 2020 Sep 29;39(1):203. doi: 10.1186/s13046-020-01714-8.
7
Context-dependent functional compensation between Ythdf mA reader proteins.Ythdf mA 读者蛋白的功能依赖于上下文的补偿。
Genes Dev. 2020 Oct 1;34(19-20):1373-1391. doi: 10.1101/gad.340695.120. Epub 2020 Sep 17.
8
Stabilization of oncogenic transcripts by the IGF2BP3/ELAVL1 complex promotes tumorigenicity in colorectal cancer.IGF2BP3/ELAVL1复合物对致癌转录本的稳定作用促进结直肠癌的致瘤性。
Am J Cancer Res. 2020 Aug 1;10(8):2480-2494. eCollection 2020.
9
YTHDF1-mediated translation amplifies Wnt-driven intestinal stemness.YTHDF1 介导的翻译扩增了 Wnt 驱动的肠干细胞特性。
EMBO Rep. 2020 Apr 3;21(4):e49229. doi: 10.15252/embr.201949229. Epub 2020 Feb 17.
10
Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer.m6A 修饰降低预示着胃癌的恶性表型，并增强了 Wnt/PI3K-Akt 信号通路。
Cancer Med. 2019 Aug;8(10):4766-4781. doi: 10.1002/cam4.2360. Epub 2019 Jun 26.